Aditxt Inc. (ADTX)vsInsmed Inc (INSM)
ADTX
Aditxt Inc.
$0.91
-5.71%
HEALTHCARE · Cap: $673,210
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 10209041% more annual revenue ($606.42M vs $5,940). ADTX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ADTX
Avoid23
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2.8% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADTX
ADTX has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ADTX
The primary concerns for ADTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ADTX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ADTX generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aditxt Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Aditxt Inc. is an innovative biotechnology company focused on advancing healthcare through its proprietary immune modulation and personalized medicine platform. The company is dedicated to enhancing immune system responses to combat chronic diseases and allergies, thereby improving patient outcomes. With a strong pipeline of therapeutic candidates backed by comprehensive research and strategic partnerships, Aditxt is strategically positioned to lead in the emerging field of immune-based therapies. By emphasizing scientific progress and patient-focused solutions, Aditxt aims to reshape the future of immunology and contribute significantly to the healthcare landscape.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?